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A B S T R A C T
The process of drug discovery and development particularly that of natural products, has evolved
markedly over the last 30 years into increasingly formulaic approaches. As a major class of natural
products initially discovered and used as early as 4000 years ago, alkaloids and the species they are
derived from have been used worldwide as a source of remedies to treat a wide variety of illnesses. Yet, a
tremendously wide discrepancy between their historical signiﬁcance and their occurrence in modern
drug development exists. Are alkaloids underrepresented in modern medicine?
The physicochemical features of 27,683 alkaloids from the Dictionary of Natural Products were cross-
referenced to pharmacologically signiﬁcant and other metrics from various databases including the
European Bioinformatics Institute’s ChEMBL and Global Biodiversity Information Facility’s GBIF. For the
ﬁrst time we show that market/developmental performance of a class of compounds is linked to its
biodiversity distributions, as deﬁned by the GBIF dataset. The potential of such a large-scale data analysis
is analyzed against both prevalent rules used to guide drug discovery processes and the larger context of
natural product development.
 2014 The Authors. Phytochemical Society of Europe. Published by Elsevier B.V. This is an open access
article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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The archeological and historical record shows that people across
Asia, Europe, and Africa used alkaloid-containing plants as early as
2000 BCE (Aniszewski, 2007). Applications of such alkaloids
included empirical medicines for animals and humans as well as
sources of poison for hunting expeditions or executions (Wink,
1998). All throughout the centuries these plants and associated
isolated compounds were increasingly and continuously used for, as
one scholar encapsulates it, ‘Murder, Magic and Medicine’ (Mann,
1992). The early 19thcentury saw breakthroughs in the isolation and§ This paper forms part of a special issue of Phytochemistry Letters dedicated to
the memory of Andrew Marston (1953–2013), outstanding phytochemist who is
much missed by his friends.
Abbreviations: Clog P, calculated log P; DNP, dictionary of natural products; GBIF,
global biodiversity information facility; HBA, hydrogen bond acceptor; HBD,
hydrogen bond donor; log D, distribution coefﬁcient; log P, partition coefﬁcient;
MWT, molecular weight; pKa, acid disassociation constant (pKa).
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creativecommons.org/licenses/by/3.0/).characterizationofpuriﬁedcompounds. Intheearlyyearsof the19th
century, Friedrich Sertu¨rner isolated what we know today as
morphine. This led to a cascade of successful isolations and
discoveries of isolated compounds by several European scientists
including the isolation of xanthine (1817), strychnine (1818),
atropine (1819), quinine (1820), and caffeine (1820) (Heinrich et al.,
2012). This burst of single compound isolation has been character-
ized by many, including Sneader, as ‘the greatest advance in the
process of drug discovery’ (Sneader, 2005).
The process of drug discovery as it stands today differs greatly
from the ones prominent throughout most of the 20th century
decades. Highly popular, yet debated empirical rules aiming to
enhance the selectivity of drug candidates have for many years been
in the spotlight. Popular terms such as ‘lead-like’ and ‘drug-like’
have gained prominence though the work of Lipinski and Congreve
(Lipinski, 2000; Rees et al., 2004). As one explores the literature, it is
very clear that what exactly druglikeness entails really depends on
the intended application of the compound. Properties appropriate
for successful metabolism of an orally administered drug differ
greatly from, for example, transdermal injections. The applicabilityElsevier B.V. This is an open access article under the CC BY license (http://
2 Alkaloid naming in both in the DnP and ChEMBL is highly inconsistent and
fragmented. This value represents the total number of exact matches between both
datasets minus those which have been labeled as ‘pharmaceutical alkaloids’.
3 The distribution coefﬁcient is the ratio of the sum of the concentrations of all
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debate in drug research and development.
One conspicuously lacking class of compounds in this debate has
been natural products, which, however, are well known to be of
major importance as medicines (e.g. Cragg and Newman, 2005;
Newman and Cragg, 2007; Saxton, 1971). It could be argued that the
sheer diversity of natural products does not allow for adherence to
such rules, yet nevertheless the importance of natural products (and
speciﬁcally alkaloids) in modern drug discovery cannot be over-
estimated as their use has been linked closely the history of human
use of such resources (Heinrich, 2013).
Following the initial discoveries and isolations there was a
gradual increase in the number of known and medicinally used
alkaloids. Currently, the Dictionary of Natural Products (DNP) lists
over 27,000 compounds as alkaloids (Hocking, 1997 and updates -
dnp.chemnetbase.com). Other datasets deﬁne and list fewer alka-
loids.1Much of the uncertainty of how many alkaloids actually exist
stems from various issues including: poor chemical identiﬁcation or
structure elucidation, lack of dereplication, chemical ambiguities,
and the varying deﬁnitions of what exactly constitutes an alkaloid
(Rates, 2001). As with natural products as a whole, many have
proposed differing classiﬁcatory schemes for alkaloids. One popular
scheme divides the whole class of compounds into three categories:
 True alkaloids (compounds which derive from amino acid and a
heterocyclic ring with nitrogen,
 Protoalkaloids (compounds, in which the N atom derived from an
amino acid is not a part of the heterocycle), and
 Pseudoalkaloids (compounds, the basic carbon skeletons of
which are not derived from amino acids) (Eagleson, 1994).
The scope of this study encompasses all such variations in
deﬁnitions by taking the widest categorization of alkaloids as a
class of compounds; essentially the 27,000+ found in the DNP (as of
April 2014).
In this article we argue that – despite their history of use – alkaloids
are considerably underrepresented as new marketed or licensed
medicines (‘drugs’). Alkaloids are relatively absent as compared with
synthetic, semi-synthetic, and other non-alkaloid natural drug leads
which successfully enter the pharmaceutical market today. We argue
that barriers to development are strongly correlated to physicochemi-
cal properties of compounds. In addition, earlier research suggests
that weediness (which in turn is linked to a species abundance) can
serve to enhance the search for novel compounds in drug discovery
(Stepp, 2004). How does this hold up against often cited challenges
associated with access, supply, and production of such alkaloids?
This article examines the similarity of physicochemical and
biodiversity characteristics of pharmaceutical and non-pharma-
ceutical alkaloids in order to pinpoint why alkaloids are underrep-
resented in the pharmaceutical arena and uses Global Biodiversity
Information Facility (GBIF) data to assess this in the context of the
species abundance in terms of its geographical distribution. GBIF is
undisputedly one of the most comprehensive datasets on the
distribution of individual species currently available. GBIF deﬁnes
an occurrence as documented evidence of a named organism in
nature. How does the phytogeographical abundance of a plant
species correlate with the ‘success’ of compounds derived from the
taxon to be developed into a marketed drug?
2. Results and discussion
2.1. Alkaloid drugs used as medicines
One would assume that with a 4000+ year history of use, often
acting as remedies for a variety of illnesses, alkaloids and alkaloid1 In 1988, NAPRALERT contained 16,000 alkaloids. As of 2001, no major additions are
made to the dataset. It is estimated that NAPRALERT contains less than 20,000 alkaloids.containing taxa would play an important and visible role in
modern drug development (Bruhn and Bruhn, 1973). Or in the
words of G. Cordell (1981) focusing on local and traditional uses:
‘For thousands of years, indigenous groups around the world
discovered, through self-experimentation with locally available
plant extracts, that they could provide materials for hunting prey,
culinary enhancement, amelioration from disease, relief of pain,
and healing. . .in this [last] 200-year period, many alkaloids
became critical components of the global pharmaceutical arma-
mentarium, and tremendous healing has resulted from their
clinical application’ (Royal Society of Chemistry, 1971). Our search
using the ‘Dictionary of Alkaloids (Buckingham, 2010) and other
sources identiﬁed a total of 53 alkaloids used currently or within
the last 50 years for pharmaceutical applications (Table 1). To date
less than 0.002% (53/27,000) of alkaloids or alkaloid-based drugs
are marketed for such uses internationally (Table 1). It is not
surprising that such a diverse set of natural products and their
derivatives yield medicines which are used in a variety of
applications ranging from cough-suppressants to antimalarial
agents. However, in the last 25 years only galanthamine and taxol
were newly introduced into biomedicine, and the former in
essence through an extension of the therapeutic claims (i.e. from
poliomyelitis to Alzheimer’s disease, Heinrich and Teoh, 2004).
There are only less than 200 others which are commonly used in
industrial processes and the manufacturing of commercial goods
(for example: N,N’-dioctadecanoylethanediamine is an antifoam-
ing agent used in the polymer industry and methylamine
hydrochloride is used in the tanning industry).
A quantitative analysis of alkaloids in modern pharmaceutical
research and development based on their physicochemical properties
One preliminary step in characterizing the physicochemical
makeup of pharmaceutical/medicinal alkaloids is to use metrics
used in the commonly used empirical rules to select for
druglikeness. At the most basic level, an initial analysis (Table 2
and Fig. 1) of 13 basic physicochemical properties of two sets of
alkaloids (those used in marketed pharmaceutical/medicinal
products (n = 53) and those which are not (n = 1968)2) shows
averages of each physicochemical property ranging from 56 to
+34% ((Pharma Avg./Total Avg.)  1). The property which exhibits
the largest difference between the two sets is the distribution
coefﬁcient (log D)3 followed by hydrogen bond donors (HBD), the
partition coefﬁcient (log P)4, and polar surface area (PSA)
respectively. The log D, HBD, log P, and PSA of marketed
pharmaceutical products is on average 31–55% lower than that
of other alkaloids. These observations do not completely deviate
from those general rules of thumb outlined above but rather
indicate that adjustments to purely computational screening
methods must be made to enhance alkaloid based drug discovery.
Average log D values for medicinal alkaloids are less than half as
compared to other non-medicinal alkaloids. Average log P values
for medicinal alkaloids are less than 40% as compared to other non-
medicinal alkaloids. This suggests that ionization, acidity (log D is
decreased as a function of increased pH), and ultimately solubility
are potentially the most weighty factors in alkaloid development.
These observations are somewhat conﬁrmed by commonly used
empirical rules in that they state that log P values should be <5.0
and <5.6 respectively (cf. Section 2.3).forms of the compound (ionized plus un-ionized) in each of the two phases.
4 The partition coefﬁcient is a ratio of concentrations of un-ionized compound
between the two solutions.
Table 1
Record of alkaloids used in marketed medicines, drugs, and clinical environments (excluding additive used in extending the storage life of drawn blood) (Based on The Royal
Society of Chemistry, 1971; Cordell, 1981; Schmeller and Wink, 1998; Buckingham, 2010). Derivatives not included.
Alkaloid name Synonyms Applications Example product
Aconitine Rheumatism, neuralgia, sciatica AconitysatTM, BronpaxTM, PectovoxTM,
VocadysTM
Adenine Antiviral agent, pharmaceutical aid used
to extend storage life of whole blood
Adenosine, Ansyr1
Ajmaline Ajimaline, Gilurytmal, Merabitol,
Raugalline, Rauwolﬁne, Rytmalin,
Tachmalin
Antiarrhythmic agent AritminaTM, GilurytmalTM, RauwopurTM,
RitmosTM
Atropine Tropine tropate Antispasmodic, anti-parkinson,
cycloplegic drug
AbdominolTM, EspasmoTM, ProtecorTM,
TonatonTM
Berberine Berbericine, Umbellatine, Eye irritations, AIDS, hepatitis KollyrTM, MurineTM, SedacollyreTM
Boldine Cholelithiasis, vomiting, constipation BoldoﬂorineTM, BoldosalTM, OxyboldineTM,
SambilTM
Caffeine Neonatal apnea, atopic dermatitis AgevisTM, AnlagenTM, ThomapyrineTM,
Vomex ATM
Canescine Harmonyl, Raunormine, Recanescine,
Reserpidine
Antihypertensive agent Deserpidine
Cathine Norpseudoephedrine, Norisoephedrine Anorectic drug AmorphanTM, EetlessTM, RecatolTM
Cinchonidine Cinchonan-9-ol Increases reﬂexes, epileptiform
convulsions
QuinimaxTM, PalujectTM
Cocaine Local anesthetic Used in highly regulated clinical
environments
Codeine Methylmorphine, Codicept, Kodein,
Tussipan
Antitussive, analgesic AntitussTM, CodicapsTM, TussipaxTM
Colchicine Amyloidosis treatment, acute gout ColBenemidTM, ColgoutTM, VerbanTM
Diethanolamine 2,2’-Dihydroxydiethylamine,
Diolamine
Base used in pharmaceuticals etc. Menbutone Diethanolamine
Emetine Ipecine, Methylcephaleine Intestinal amoebiasis, expectorant drug CophylacTM, IpecacTM, RectopyrineTM
Ephedrine Nasal decongestant, bronchodilator AmidoynaTM, BronchicumTM, PeripherinTM,
SolaminTM
Ergometrine Ergonovine, Ergotrate, Ergobasine,
Ergotocin, Ergostetrine
Postpartum/postabortal hemorrhage ErgometronTM, Ergotrate MaleatTM,
SyntometrineTM
Ergotamine Migrane treatment ErgostatTM, LingraineTM, MigralTM,
VirdexTM
Eserine Physostigmine Ophthalmology, antidote/poisoning AnticholiumTM, AntiliriumTM, PiloserineTM
Galanthamine Galantamine, Jilkon, Karantonin,
Lycoremine
Muscle relaxant, Alzheimer’s NivalinaTM
Hydrastine Gastrointestinal disorders Gine SedansTM, KollyrTM
Hyoscine Scopolamine Motion sickness, BuscopanTM, HyospasmolTM, LotanalTM,
TranscopTM
Hyoscyamine Daturine, Duboisine Antispasmodic, anti-parkinson,
cycloplegic drug
BellatardTM, CystospazTM, DonnatabTM,
UrisedTM
Lobeline Anti-smoking, asthma, cough CitotalTM, LobatoxTM, RefraneTM,
StopsmokeTM
Morphine Pain relief, diarrhea DiastatTM, DuromorphTM, OramprphTM,
SpasmofenTM
N,N-
Diallylbisnortoxinerine
Alcuronium chloride Short acting muscular relaxant Alloferin
Narceine Cough suppressant PenerajTM
Nicotine Anti-smoking NicabateTM, NicodermTM, NicoretteTM,
StubitTM
Noscapine Narcotine Cough suppressant BequitusinTM, DegoranTM, TossamineTM,
TussisedalTM
Papaverine Papaveroline tetramethyl ether Vasodilator, gastrointestinal disorders ActicarbineTM, OpdensitTM, PameionTM,
VasocalmTM
Pelletierine Tenia infestations Pelletierine tannate USP
Pilocarpine Ocucarpine, Pilocarpol, Syncarpine Miotic in treatment of glaucoma, leprosy FriktonTM, PiladrenTM, Salegen,
ThiloadrenTM, VistacarpinTM
Quinidine Conquinine, Conchinine, Pitayine Ventricular and supraventricular
arrhythmias, malaria, cramping
CardioquinTM, DuraquinTM, QuindexTM,
Rhythomochin 1TM
Quinine 6’-Methoxycinchonan-9-ol, Chinin Malaria, babesiosis, myotonic disorders AdaquinTM, BiquinateTM, QuinoctalTM,
Zynedo-BTM
Raubasine Ajmalicine Vascular disorders CircoleneTM, CristanylTM, DuxilTM, SarpanTM
Rescinnamine Reserpinine, Anaprel, Apoterin,
Cinnaloid, Rescaloid, Moderil,
Scinnamina
Hypertension DetensitralTM, DiuraupurTM, RauwopurTM
Reserpine Hypertension, psychoses AbicolTM, BriserinTM, SandrilTM, TerbolanTM
Rotundine Argemonine, Bisnorargemonine, Analgesic, sedative, hypnotic agent Rotundin-BVP, Transda
Sanguinarine Antiplaque agent Toothpastes and mouthwashes
Sparteine Uterine contractions, cardiac arrhythmias AnxoralTM, DiffucordTM, NormotinTM,
TachynergTM
Strychnine Strychnidin-10-one Eye disorders DysurgalTM, PasumaTM RetinovixTM,
SeniraktTM
Synephrine Vasoconstrictor, conjunctival
decongestant, weight loss
Oxedrine, Sympatol
Taxol Paclitaxel, Taxol A, Anzatax, Yewtaxan Mamma and ovary carcinoma TaxolTM
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Table 1 (Continued )
Alkaloid name Synonyms Applications Example product
Theobromine Asthma, diuretic agent AtrofedTM, CircovegetalinTM, DynamolTM,
UrodonalTM
Theophylline Austyn, Elan, Elixophyllin, Euphyllin,
Nuelin
Asthma, bronchospasms AdenovasinTM, AerobinTM, EuphyllinTM,
TheochronTM
Turbocuranine Tubarine Muscle relaxant JexinTM, TubarineTM
Vinblastine Hodgkin’s disease, testicular cancer,
blood disorders
PeriblastineTM, VelbanTM, VelbeTM,
VelsarTM
Vincamine Vasodilator AethromaTM, AngiopacTM, PervinTM,
VincimaxTM
Vincristine Burkitt’s lymphoma NorcristineTM, OncovinTM, VincrisulTM
Vindesine Chemotherapy DAVA, Eldesine, Eldisine
Yohimbine Aphrodine, Corymbin, Corynine,
Yohimex, Hydroergotocin,
Quebrachine, Yohimvetol
Aphrodisiac, urinary incontinence AphrodyneTM, PasumaTM, ProwessTM,
YohimexTM
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Druglikeness rules such as the Rule of Three (Ro3) and Rule of
Five (Ro5) were not designed with natural products in mind. Yet,
we see that the medicinal alkaloids have 56% less R5 violations
when compared with alkaloids at large, thus suggesting that such
empirical rules (rules of thumb) are somewhat effective indicators
in alkaloid development processes. In looking strictly at MWT
values in the DNP for all 27,683 alkaloids we see that 27% pass the
Ro3 while 77% pass the Ro5. When added chemical descriptors
from ChEMBL are looked at Ro3/Ro5 pass rates decrease to 5% and
60% respectively. It is impressive that pharmaceutical/medicinal
alkaloids have 56% less Ro5 violations and a 60% pass rate. If so
many alkaloids pass the Ro5, are there other non-physicochemical
factors which hinder their development?
Thus, in working toward deepening our understanding of to
what extent such rules can be enhanced for research and
development, a few modiﬁcations to such empirical rules, based
on the current dataset, are proposed:
By using the following ﬁve parameters, we can predict over 90%
of the pharmaceutical/medicinal alkaloids in our dataset. Many of
the rules are extensions of the commonly used Ro3/Ro5 metrics
which prioritize factors such as compound size and solubility.
1. MWT/PSA  3
2. HBD  4
3. BpKa 6–10
4. log P -1–7
5. Ratio MW/Heavy Atoms 13.2–13.9Table 2
Comparison of average of physicochemical properties between pharmaceutical and/or 
Variable Pharmaceuticals/drugs in ChEMBL (n = 53) 
Range 90% of values
fall within (SD)
Category
average
MWT 162.23–809.41 (164.78) 375.88 
Alog P 0.02 to 4.89 (1.46) 1.46 
PSA 32.78–153.45 (42.24) 65.91 
HBA 2–12 (2.93) 5.17 
HBD 0–3 (1.02) 1.19 
#Rotatable Bonds 0–10 (3.33) 4 
ApKa 8.60–13.93 (2.44) 11.44 
BpKa 5.90–9.98 (1.54) 7.91 
ACDlog P 0.65 to 5.75 (2.03) 1.84 
log D 1.09 to 5.2 (2.06) 0.98 
Aromatic rings 1–4 (0.99) 1.89 
Heavy atoms 13–46 (11.92) 27.60 
QED weighted 0.25–0.88 (0.22) 0.66 
#Ro5 violations 0–2 (0.65) 0.28 When such rules are used to ﬁlter the ChEMBL dataset of the
2020 alkaloids included 672 (33%) comply with this rule. Rule 3
(pKa 6–10) is the most selective in that it ﬁlters out 25% of the total
alkaloids. The 672 alkaloids represent exactly one third of the total
dataset. If this number is 100% accurate and assuming that there
are no supply, commercial, and/or identiﬁcation issues that leaves
over 600 alkaloid candidates that have the chemical proﬁle to serve
in some commercial pharmaceutical/medicinal capacity. Extrapo-
lating this liberal estimate to the larger DNP dataset suggests, a
that there are 6000–7000 alkaloids which carry this ‘development
potential’, as deﬁned as physicochemical druglikeness similar to
the Ro3/Ro5 empirical rules.
The goal of this exercise, far from merely introducing another
empirical rule into the druglikeness debate, is rather to highlight
that several dozen alkaloids used across a variety of pharmaceu-
tical/medicinal applications have corresponding physicochemi-
cal properties. Therefore, the empirical rule proposed above
selects for >90% of the 53 medicinal as compared to 60% with
the Ro5.
2.3. Is this linked to a species abundance?
The more difﬁcult question regarding the quantiﬁcation of
alkaloid biodiversity and the utility and limitations of the GBIF
database has already been outlined in previous sections. It is
important to note that data has only been extracted for 7435 of the
total alkaloid set (dataset is 14.6% complete). Preliminary results
are shown in Fig. 2. We see that 93% of all pharmaceutical/
medicinal alkaloids have more than 50 occurrences in the GBIFmedicinally signiﬁcant/insigniﬁcant alkaloids.
Other alkaloids in ChEMBL (n = 1968) % Difference in Avg.
(Pharma Avg./
Total Avg.)  1)
Range 90% of
values fall within (SD)
Category
average
219.23–840.70 (178.70) 446.26 15.77
0.92 to 7.2 (2.42) 2.97 14.38
28.23–243.51 (61.11) 96.29 31.55
2–13 (3.40) 5.76 10.24
0–6 (1.90) 2.27 47.32
0–16 (5.10) 4.87 17.92
3.41–13.71 (3.54) 10.12 13.02
1.01–10.56 (3.31) 6.41 23.39
1.21 to 7.72 (2.85) 3.11 40.66
2.52 to 7.33 (2.89) 2.22 55.75
0–4 (1.32) 1.61 17.42
16–59 (12.54) 31.62 12.68
0.11–0.85 (0.23) 0.49 35.26
0–2 (0.90) 0.64 56.01
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Fig. 1. % Difference in averages of physicochemical properties between pharmaceutical/medicinally signiﬁcant and insigniﬁcant alkaloids.
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Fig. 2. Molecular weight (g/mol) and GBIF occurrences (limited data set (n = 7435) note logarithmic scale). Stripes of horizontal data points refer to families of alkaloids all
derived from the same natural sources. Squares represent alkaloids in the pharmaceutical arena. Diamonds represent non-pharmaceutical alkaloids.
5 http://www.gbif.org/whatisgbif. Accessed December 14th 2013.
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have less than 10 occurrences in the GBIF database.
When averaging the two data sets the average occurrence of the
pharmaceutical alkaloids set is 17,952 (s.d. = 35,595) occurrences
while the non-pharmaceutical set averages at 4,165 occurrences
(s.d. = 15,072). The standard deviation of the non-pharmaceutical
set is signiﬁcantly higher when calculated as a percent of the
category average. This is logical considering the wide variation of
abundances of alkaloid producing plants around the globe. These
results lend support to those who argue that supply issues are the
dominating indicator of successful research, development, and
commercialization of natural products.
Many such as Principe (1991) have cited supply constraints as a
key obstacle in the development of natural products. For example,
Harvey states that natural products are unattractive to many
pharmaceutical companies because of perceived difﬁculties
relating to the complexities of natural product chemistry and to
the access and supply of natural products resulting in technicaldifﬁculties relating to the (larger scale) isolation of bioactive
natural products (Harvey, 2008). One effort which shows much
promise was put forth by the Global Biodiversity Information
Facility (GBIF), which describes itself as operating ‘through a
network of nodes, coordinating the biodiversity information
facilities of participant countries and organizations, collaborating
with each other and the Secretariat to share skills, experiences and
technical capacity.’5 Biodiversity data is served through four
‘portals’; occurrences, datasets (smaller datasets endorsed and
subsequently published by GBIF.
3. Conclusions
Overall, these data demonstrate that alkaloids are under
represented in the context of newly introduced medicines.
Although commonly employed empirical rules used to hone in
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than 50% of all alkaloids, other factors must be analyzed to more
accurately pinpoint how best to tap into the vast remainder of
undeveloped alkaloids.
For the ﬁrst time we show that biodiversity distributions, as
deﬁned by the GBIF dataset, help in understanding to what extent a
taxon’s distribution relates to market/developmental perfor-
mance. 93% of the pharmaceutical/medicinal alkaloids have >50
GBIF occurrences (Principe, 1991), indicating that a taxon’s
abundance considerably affects the development of an alkaloid
into a medical product. This supports the view that supply
constraints are a considerable concern given that most plants of
interest today are usually indigenous only to biodiversity-rich
countries especially of the tropics and subtropics.
Thus a larger sample size, both of calculated/observed chemical
properties and host plant species distribution data will increase the
accuracy of such an analysis. The speciﬁcity of pharmacological
action of alkaloids and potential toxicological concerns have not
been addressed in this context and in subsequent analyses these
may need to be taken into consideration. It is likely that as empirical
rules in drug development have been developed over the last 15
years to better hone in on drug-like compounds, rules and
additional insights regarding natural products and speciﬁc natural
product classes such as alkaloids will begin to emerge to drive
development in this under-tapped area drug development.
Presumably, future discovery of drug-like alkaloids will begin with
abundant, easily accessible and scalable plants rather than a set of
speciﬁc empirical rules which narrow down compounds of interest.
4. Materials/methods
The initial data set of 27,683 alkaloids was imported from the
Dictionary of Natural Products web portal (dnp.chemnetbase.com/)
into Microsoft Excel 2010. A maximum of 33 data types, both
qualitative and qualitative, were extracted for each of the 27,683
alkaloids. Highly incomplete (ex. solubility) and irrelevant (ex. DnP
classiﬁcation codes) data types were omitted. Modiﬁcations were
made to the format of some data to ensure consistency.
Data from ChEMBL (https://www.ebi.ac.uk/chembl/) was man-
ually queried for each of the compounds listed in the initial DNP
extract (synonyms from each of the two datasets also included).
Due to the wide variance between keywords and formats between
the two datasets, automating this process would not yield many
‘hits.’ Therefore, this initial ‘bridging’ of datasets was performed
manually in the form of each query and subsequent data import
being performed manually. This initial effort yielded 2020 ‘hits’
(7%) and it is estimated that there are <500 potential remaining
compounds that exist both in DnP and ChEMBL datasets. Similar to
the DNP, not all data types in ChEMBL were deemed relevant and
analyzed (ex. Molregno, Max Phase, and Med Chem Friendly).GBIF (www.gbif.org/occurrence) data was manually queried
and exported from the web portal into Microsoft Excel. Currently it
contains 424,254,844 occurrences of organisms in nature including
117,909,945 (27.8%) records from the kingdom Plantae. Occur-
rences include collected and documented specimens, citations, and
records in nature. For example: the DNP reports that the alkaloid
monocrotaline can be found under the heading of ﬁve taxa:
Crotalaria retusa L., Crotalaria spectabilis Roth, Crotalaria aegyptiaca
Benth., Crotalaria burhia Benth. (all Fabaceae) and Lindeloﬁa
spectabilis (Boraginaceae). Occurrences in GBIF for these ﬁve plant
species total to 3222 (2575, 440, 144, 27, and 36 respectively). A
preliminary calculation of this nature was possible for 27% of all
the alkaloids listed in the DNP (7435/27,783).
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